

# Jamie O'Hara

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1562747/publications.pdf>

Version: 2024-02-01

30  
papers

407  
citations

1162367

8  
h-index

794141

19  
g-index

30  
all docs

30  
docs citations

30  
times ranked

460  
citing authors

#	ARTICLE	IF	CITATIONS
1	The cost of severe haemophilia in Europe: the CHES study. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 106.	1.2	105
2	The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 84.	1.0	62
3	Achieving the unimaginable: Health equity in haemophilia. <i>Haemophilia</i> , 2020, 26, 17-24.	1.0	54
4	The relationship between target joints and direct resource use in severe haemophilia. <i>Health Economics Review</i> , 2018, 8, 1.	0.8	39
5	Evidence of a disability paradox in patient-reported outcomes in haemophilia. <i>Haemophilia</i> , 2021, 27, 245-252.	1.0	25
6	Long-term outcomes from prophylactic or episodic treatment of haemophilia A: A systematic review. <i>Haemophilia</i> , 2018, 24, e301-e311.	1.0	18
7	Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis. <i>Haemophilia</i> , 2021, 27, 113-119.	1.0	15
8	Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHES US and CHES US+ population surveys. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 143.	1.2	15
9	Real-world comparative analysis of bleeding complications and health-related quality of life in patients with haemophilia A and haemophilia B. <i>Haemophilia</i> , 2018, 24, e322-e327.	1.0	8
10	Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. <i>Journal of Medical Economics</i> , 2021, 24, 363-372.	1.0	8
11	The lived experience of women with a bleeding disorder: A systematic review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12652.	1.0	8
12	Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHES II real-world burden of illness study in Europe. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 521.	1.2	8
13	Economic burden of hemophilia B in the US: a systematic literature review. <i>Journal of Drug Assessment</i> , 2019, 8, 28-28.	1.1	6
14	The views of women with bleeding disorders: Results from the Cinderella study. <i>Haemophilia</i> , 2022, 28, 316-325.	1.0	5
15	Examining patient and professional perspectives in the UK for gene therapy in haemophilia. <i>Haemophilia</i> , 2022, 28, 588-609.	1.0	5
16	The impact of factor infusion frequency on health-related quality of life in people with haemophilia. <i>The Journal of Haemophilia Practice</i> , 2020, 7, 102-109.	0.2	4
17	Problem Joints and Their Clinical and Humanistic Burden in Children and Adults with Moderate and Severe Hemophilia a: CHES Paediatrics and CHES II. <i>Blood</i> , 2020, 136, 33-34.	0.6	4
18	Differential humanistic and economic burden of mild, moderate and severe haemophilia in european adults: a regression analysis of the CHES II study. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 148.	1.2	4

#	ARTICLE	IF	CITATIONS
19	Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHES-PAEDs study. Orphanet Journal of Rare Diseases, 2022, 17, 150.	1.2	3
20	An Insight into the Impact of Hemophilia a on Daily Life According to Disease Severity: A Preliminary Analysis of the CHES II Study. Blood, 2020, 136, 1-3.	0.6	2
21	A Descriptive Comparison of Disease Burden Between Hemophilia Patients with and without Inhibitors: Data from the CHES Study. Blood, 2016, 128, 4756-4756.	0.6	2
22	Bleeding Data across Baseline FIX Expression Levels in People with Hemophilia B: An Analysis Using the 'Factor Expression Study'. Blood, 2021, 138, 592-592.	0.6	2
23	Examination and Validation of a Patient-Centric Joint Metric: "Problem Joint"; Empirical Evidence from the CHES US Dataset. Blood, 2020, 136, 25-26.	0.6	2
24	Prophylactic Treatment in People with Severe Hemophilia B in the US: An Analysis of Real-World Healthcare System Costs and Clinical Outcomes. Blood, 2019, 134, 2118-2118.	0.6	1
25	“You’re only a carrier” women and the language of haemophilia. The Journal of Haemophilia Practice, 2021, 8, 128-132.	0.2	1
26	Adherence and a Potential Trade-Off Currently Faced in Optimizing Hemophilia Treatment. Blood, 2020, 136, 40-41.	0.6	1
27	Effect of Moderate and Severe Hemophilia a on Daily Life in Children and Their Caregivers: A CHES Paediatrics Study Analysis. Blood, 2020, 136, 43-45.	0.6	0
28	<i>Evidence of a Hemophilia Employment Gap: Comparing Data from CHES US+ and the 2019 Current Population Survey</i> . Blood, 2020, 136, 26-27.	0.6	0
29	New challenges for an expanding generation of older persons with haemophilia. The Journal of Haemophilia Practice, 2022, 9, 1-13.	0.2	0
30	Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B. Journal of Medical Economics, 2022, 25, 386-392.	1.0	0